Villar Inmaculada C, Panayiotou Catherine M, Sheraz Adil, Madhani Melanie, Scotland Ramona S, Nobles Muriel, Kemp-Harper Barbara, Ahluwalia Amrita, Hobbs Adrian J
Clinical Pharmacology, William Harvey Research Institute, Bart's and The London, Charterhouse Square, London EC1M 6BQ, UK.
Cardiovasc Res. 2007 Jun 1;74(3):515-25. doi: 10.1016/j.cardiores.2007.02.032. Epub 2007 Mar 3.
C-type natriuretic peptide (CNP) has recently been suggested to represent an endothelium-derived hyperpolarising factor (EDHF) in the mammalian resistance vasculature and, as such, important in the regulation of local blood flow and systemic blood pressure. Additionally, this peptide has been shown to protect against ischaemia-reperfusion injury and inhibits leukocyte and platelet activation. Herein, we use a novel, selective natriuretic peptide receptor-C (NPR-C) antagonist (M372049) to highlight the pivotal contribution of CNP/NPR-C signalling in the EDHF-dependent regulation of vascular tone and investigate the mechanism(s) underlying the release and biological activity of CNP.
In vitro pharmacological investigation was conducted in rat (Sprague-Dawley) aorta and mesenteric resistance arteries. Relaxant responses to CNP, atrial natriuretic peptide (ANP), the nitric oxide donor spermine-NONOate (SPER-NO) and the endothelium-dependent vasodilator, acetylcholine (ACh) were examined in the absence and presence of M372049 or inhibitor cocktails shown previously to block endothelium-dependent dilatation in the resistance vasculature. RT-PCR was employed to characterize the expression of NPR subtypes in the vessels studied.
M372049 produced concentration-dependent inhibition of the vasorelaxant activity of CNP in rat isolated mesenteric resistance arteries but not aorta; in contrast, M372049 did not affect relaxations to ANP or SPER-NO in either vessel. M372049 or ouabain alone produced small, significant inhibition of EDHF-dependent relaxations in mesenteric arteries and in combination acted synergistically to abolish such responses. A combination of M372049 with established inhibitors of EDHF-dependent relaxation revealed that multiple, distinct pathways coordinate the bioactivity of EDHF in the resistance vasculature, and that CNP/NPR-C signalling represents a major component.
These data substantiate CNP/NPR-C signalling as a fundamental pathway underlying EDHF-dependent regulation of vascular tone in the rat mesenteric resistance vasculature. An increased understanding of the physiological roles of CNP/NPR-C signalling in the vasculature (now facilitated by the identification of a selective NPR-C antagonist) should aid determination of the (patho)physiological importance of EDHF and might provide the rationale for the design of novel therapeutics.
最近有研究表明,C型利钠肽(CNP)在哺乳动物阻力血管中代表一种内皮源性超极化因子(EDHF),因此在局部血流和全身血压的调节中起重要作用。此外,该肽已被证明可预防缺血再灌注损伤,并抑制白细胞和血小板活化。在此,我们使用一种新型的选择性利钠肽受体-C(NPR-C)拮抗剂(M372049)来突出CNP/NPR-C信号在EDHF依赖性血管张力调节中的关键作用,并研究CNP释放和生物活性的潜在机制。
在大鼠(Sprague-Dawley)主动脉和肠系膜阻力动脉中进行体外药理学研究。在不存在和存在M372049或先前显示可阻断阻力血管中内皮依赖性扩张的抑制剂混合物的情况下,检测对CNP、心房利钠肽(ANP)、一氧化氮供体精胺-亚硝基铁氰化钠(SPER-NO)和内皮依赖性血管舒张剂乙酰胆碱(ACh)的舒张反应。采用逆转录-聚合酶链反应(RT-PCR)来表征所研究血管中NPR亚型的表达。
M372049对大鼠离体肠系膜阻力动脉中CNP的血管舒张活性产生浓度依赖性抑制,但对主动脉无此作用;相反,M372049对任一血管中ANP或SPER-NO引起的舒张均无影响。单独使用M372049或哇巴因对肠系膜动脉中EDHF依赖性舒张产生小幅度但显著的抑制,联合使用则协同作用消除此类反应。M372049与已确立的EDHF依赖性舒张抑制剂联合使用表明,多种不同途径协同调节阻力血管中EDHF的生物活性,且CNP/NPR-C信号是主要组成部分。
这些数据证实CNP/NPR-C信号是大鼠肠系膜阻力血管中EDHF依赖性血管张力调节的基本途径。对CNP/NPR-C信号在血管中的生理作用的进一步了解(现在通过鉴定选择性NPR-C拮抗剂得以促进)应有助于确定EDHF的(病理)生理重要性,并可能为新型治疗药物的设计提供理论依据。